11-dehydro-txb2

Introduction

To understand associated biological information of 11-dehydro-txb2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with 11-dehydro-txb2?

11-dehydro-txb2 is suspected in Risk factor, cardiovascular, Acute coronary syndrome, thrombocytosis, Chronic ischemic heart disease NOS, Diabetes Mellitus, Diabetes Mellitus, Non-Insulin-Dependent and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 11-dehydro-txb2

MeSH term MeSH ID Detail
Hypoalphalipoproteinemias D052456 5 associated lipids
Renal Artery Obstruction D012078 8 associated lipids
Blood Platelet Disorders D001791 12 associated lipids
Death, Sudden, Cardiac D016757 12 associated lipids
Polycythemia Vera D011087 13 associated lipids
Cerebral Hemorrhage D002543 13 associated lipids
Atrial Fibrillation D001281 16 associated lipids
Albuminuria D000419 18 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Per page 10 20 | Total 20

PubChem Associated disorders and diseases

What pathways are associated with 11-dehydro-txb2

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with 11-dehydro-txb2?

There are no associated biomedical information in the current reference collection.

What functions are associated with 11-dehydro-txb2?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with 11-dehydro-txb2?

There are no associated biomedical information in the current reference collection.

What genes are associated with 11-dehydro-txb2?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with 11-dehydro-txb2?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with 11-dehydro-txb2

Download all related citations
Per page 10 20 50 100 | Total 283
Authors Title Published Journal PubMed Link
Baltzer WI et al. Measurement of urinary 11-dehydro-thromboxane B2 excretion in dogs with gastric dilatation-volvulus. 2006 Am. J. Vet. Res. pmid:16426215
Hoh CM et al. Evaluation of effects of low-dose aspirin administration on urinary thromboxane metabolites in healthy dogs. 2011 Am. J. Vet. Res. pmid:21801060
Lupinetti MD et al. Thromboxane biosynthesis in allergen-induced bronchospasm. Evidence for platelet activation. 1989 Am. Rev. Respir. Dis. pmid:2508524
Kumlin M et al. Urinary excretion of leukotriene E4 and 11-dehydro-thromboxane B2 in response to bronchial provocations with allergen, aspirin, leukotriene D4, and histamine in asthmatics. 1992 Am. Rev. Respir. Dis. pmid:1320824
Schweer H et al. Tandem mass spectrometric determination of 11-dehydrothromboxane B2, an index metabolite of thromboxane B2 in plasma and urine. 1987 Anal. Biochem. pmid:3674365
Cavalca V et al. Simultaneous quantification of 8-iso-prostaglandin-F(2alpha) and 11-dehydro thromboxane B(2) in human urine by liquid chromatography-tandem mass spectrometry. 2010 Anal. Biochem. pmid:19825360
Lawson JA et al. Long-lived enzymatic metabolites of thromboxane B2 in the human circulation. 1986 Anal. Biochem. pmid:3087234
Hayashi Y et al. Immunoaffinity purification of 11-dehydro-thromboxane B2 from human urine and plasma for quantitative analysis by radioimmunoassay. 1990 Anal. Biochem. pmid:2372112
Riutta A et al. Solid-phase extraction of urinary 11-dehydrothromboxane B2 for reliable determination with radioimmunoassay. 1992 Anal. Biochem. pmid:1519756
Di Minno MN et al. Increased platelet reactivity in Klinefelter men: something new to consider. 2015 Andrology pmid:26216452
Carroll RC et al. A comparison of VerifyNowR with PlateletMappingR--detected aspirin resistance and correlation with urinary thromboxane. 2013 Anesth. Analg. pmid:23302970
Foulon I et al. Increased in vivo production of thromboxane in patients with sickle cell disease is accompanied by an impairment of platelet functions to the thromboxane A2 agonist U46619. 1993 Arterioscler. Thromb. pmid:8443146
Bröijersén A et al. No influence of simvastatin treatment on platelet function in vivo in patients with hypercholesterolemia. 1997 Arterioscler. Thromb. Vasc. Biol. pmid:9081681
Davi G et al. In vivo formation of 8-Epi-prostaglandin F2 alpha is increased in hypercholesterolemia. 1997 Arterioscler. Thromb. Vasc. Biol. pmid:9409316
Davì G et al. Helicobacter pylori infection causes persistent platelet activation in vivo through enhanced lipid peroxidation. 2005 Arterioscler. Thromb. Vasc. Biol. pmid:15472127
Stein CM et al. Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma. 1996 Arthritis Rheum. pmid:8670323
Cracowski JL et al. Enhanced in vivo lipid peroxidation in scleroderma spectrum disorders. 2001 Arthritis Rheum. pmid:11352247
Ferro D et al. Determinants of enhanced thromboxane biosynthesis in patients with systemic lupus erythematosus. 1999 Arthritis Rheum. pmid:10616019
Jörres A et al. Urinary excretion of thromboxane and markers for renal injury in patients undergoing cardiopulmonary bypass. 1994 Artif Organs pmid:7527629
Takayama K et al. Changes in endothelial vasoactive substances under recombinant human erythropoietin therapy in hemodialysis patients. 1991 Jul-Sep ASAIO Trans pmid:1836334
Falco A et al. Inhibition of thromboxane biosynthesis by triflusal in type 2 diabetes mellitus. 2005 Atherosclerosis pmid:16285996
Markuszewski L et al. Reduced blood platelet sensitivity to aspirin in coronary artery disease: are dyslipidaemia and inflammatory states possible factors predisposing to sub-optimal platelet response to aspirin? 2006 Basic Clin. Pharmacol. Toxicol. pmid:16635110
Calapai G et al. Cardiovascular biomarkers in groups of established smokers after a decade of smoking. 2009 Basic Clin. Pharmacol. Toxicol. pmid:19175368
Liu TF et al. [Correlation between the level of the urinary 11-dehydrothromboxane B2 and the clinical efficacy of aspirin in patients with type 2 diabetes and coronary artery disease]. 2015 Beijing Da Xue Xue Bao pmid:26679651
Varma D et al. Comparison of UHPLC and HPLC methods for the assay of prostanoids: "are the methods equivalent in terms of accuracy and precision?". 2011 Bioanalysis pmid:21510759
Ciabattoni G et al. Fractional conversion of thromboxane B2 to urinary 11-dehydrothromboxane B2 in man. 1989 Biochim. Biophys. Acta pmid:2752040
Patrignani P et al. Fractional conversion of thromboxane A2 and B2 to urinary 2,3-dinor-thromboxane B2 and 11-dehydrothromboxane B2 in the cynomolgus monkey. 1989 Biochim. Biophys. Acta pmid:2752041
Wu P et al. Purification and characterization of an NAD(+)-dependent dehydrogenase that catalyzes the oxidation of thromboxane B2 at C-11 from porcine liver. Development and application of 11-dehydro-thromboxane B2 radioimmunoassay to enzyme assay. 1990 Biochim. Biophys. Acta pmid:2223826
Lorenz RL et al. A critical evaluation of urinary immunoreactive thromboxane: feasibility of its determination as a potential vascular risk indicator. 1989 Biochim. Biophys. Acta pmid:2597697
Ciabattoni G et al. Radioimmunoassay of 11-dehydrothromboxane B2 in human plasma and urine. 1987 Biochim. Biophys. Acta pmid:3567215
Lüdicke F et al. A Japanese cross-sectional multicentre study of biomarkers associated with cardiovascular disease in smokers and non-smokers. 2015 Biomarkers pmid:26616146
Milani M et al. Effects of two different HMG-CoA reductase inhibitors on thromboxane production in type IIA hypercholesterolemia. 1996 Biomed. Pharmacother. pmid:8952866
Dragani A et al. The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy. 2010 Blood pmid:19887674
Landolfi R et al. Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo. 1992 Blood pmid:1327286
Wang ZY et al. Comparative study of platelet activation markers in diabetes mellitus patients complicated by cerebrovascular disease. 2001 Blood Coagul. Fibrinolysis pmid:11685040
Dharmasaroja PA and Sae-Lim S Effects of different doses, enteric-coated preparation of aspirin, and sex on urinary 11-dehydrothromboxane B2 in healthy volunteers. 2010 Blood Coagul. Fibrinolysis pmid:20689403
Bridges AB et al. Circadian variation of endothelial cell function, red blood cell deformability and dehydro-thromboxane B2 in healthy volunteers. 1991 Blood Coagul. Fibrinolysis pmid:1932530
Dharmasaroja PA et al. Aspirin nonresponders in patients with ischaemic stroke. 2013 Blood Coagul. Fibrinolysis pmid:23429255
Warner JH et al. Adaptive regression modeling of biomarkers of potential harm in a population of U.S. adult cigarette smokers and nonsmokers. 2010 BMC Med Res Methodol pmid:20233412
Wallén NH et al. Effects of treatment with oral isosorbide dinitrate on platelet function in vivo; a double-blind placebo-controlled study in patients with stable angina pectoris. 1994 Br J Clin Pharmacol pmid:7946939
Floyd CN et al. Increased platelet expression of glycoprotein IIIa following aspirin treatment in aspirin-resistant but not aspirin-sensitive subjects. 2014 Br J Clin Pharmacol pmid:25099258
Martinuzzo ME et al. Increased lipid peroxidation correlates with platelet activation but not with markers of endothelial cell and blood coagulation activation in patients with antiphospholipid antibodies. 2001 Br. J. Haematol. pmid:11564073
Coppola A et al. Reduced in vivo oxidative stress following 5-methyltetrahydrofolate supplementation in patients with early-onset thrombosis and 677TT methylenetetrahydrofolate reductase genotype. 2005 Br. J. Haematol. pmid:16173969
Helgason CM et al. Platelet aggregation and recruitment with aspirin-clopidogrel therapy. 2008 Cerebrovasc. Dis. pmid:18349532
Dippel DW et al. What is the lowest dose of aspirin for maximum suppression of in vivo thromboxane production after a transient ischemic attack or ischemic stroke? 2004 Cerebrovasc. Dis. pmid:15026612
Ferretti A and Flanagan VP Mass spectrometric evidence for the anomalous chemical behavior of 11-dehydrothromboxane B2. 1995 Chem. Phys. Lipids pmid:7586090
Tanaka S et al. High dose of inhaled fluticasone reduces high levels of urinary leukotriene E4 in the early morning in mild and moderate nocturnal asthma. 2003 Chest pmid:14605047
Obase Y et al. Effects of cysteinyl-leukotriene receptor antagonist, thromboxane A2 receptor antagonist, and thromboxane A2 synthetase inhibitor on antigen-induced bronchoconstriction in patients with asthma. 1998 Chest pmid:9792572
Kurokawa K et al. Circadian characteristics of urinary leukotriene E(4) in healthy subjects and nocturnal asthmatic patients. 2001 Chest pmid:11742908
Obase Y et al. Effects of pranlukast on chemical mediators in induced sputum on provocation tests in atopic and aspirin-intolerant asthmatic patients. 2002 Chest pmid:11796443